Cannabidiol derivatives, their preparation and use
Structurally modified cannabidiol derivatives address the solubility and bioavailability issues of CBD, enhancing its therapeutic efficacy for neurological disorders such as epilepsy and Parkinson's disease.
Patent Information
- Application Number
- JP2024534553
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-10
- Filing Date
- 2022-11-17
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2042-11-17
AI Technical Summary
Cannabidiol (CBD) has low water solubility and bioavailability, limiting its application in medical and other fields due to its insolubility in water and common organic solvents, and high purity CBD is almost insoluble in ethanol, methanol, ethyl ether, benzene, and chloroform.
Development of cannabidiol derivatives with specific structural modifications, including alkylene and alkyl substitutions, to enhance solubility and bioavailability, and the creation of stereoisomers, salts, esters, and prodrugs for improved pharmaceutical formulations.
The modified cannabidiol derivatives demonstrate enhanced solubility and bioavailability, effectively shortening epileptic seizure duration and improving symptoms in animal models, and show potential therapeutic benefits for neurological diseases like epilepsy and Parkinson's disease.
Smart Images

Figure 2024543655000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the technical field of chemical medicine, in particular to cannabidiol derivatives, their preparation Methods and uses, particularly for the prevention and treatment of nervous system disorders (e.g., epilepsy, Parkinson's disease) Use in medical treatment. [Background technology]
[0002] Cannabinoids contain alkyl and monoterpene groups. Currently, there are over 100 types of cannabinoids from the cannabis plant. Cannabinoids have been isolated, mainly delta-9-tetrahydrocannabinol (THC), cannabinoids Cannabidiol (CBD), cannabichromene (CBC), cannabigerol (CBG) , cannabinol (CBN), and among them, THC and CBD are the most abundant. Research has shown that cannabinoids have a wide range of pharmacological actions.
[0003] Cannabidiol (CBD) has the chemical name 2-[(1R,6R)-3-methyl-6-(1 -Methylvinyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzene It is a diol, has a CAS registration number of 13956-29-1, and has the chemical structure shown below. can be. JPEG2024543655000002.jpg4846
[0004] Research has shown that CBD has antispasmodic, anti-anxiety, anti-inflammatory, antioxidant, and other pharmacological properties. However, high-purity CBD is not available in white or red. It is a pale yellow crystal with a melting point of 66-67°C and is almost insoluble in water or 10% sodium hydroxide solution. It is almost insoluble in ethanol, methanol, ethyl ether, benzene, chloroform and petroleum. CBD is soluble in ether and other organic solvents. It has low water solubility and is bioavailable. The low irritability of CBD severely limits its applications in medicine and other fields. . Summary of the Invention
[0005] In order to solve the shortcomings of the prior art, the present invention provides a cannabidiol derivative, its preparation method and and use, in particular in the prevention and treatment of disorders of the nervous system (e.g. epilepsy, Parkinson's disease). Provide for the use of
[0006] In a first aspect of the invention, there is provided a compound having the structure: JPEG2024543655000003.jpg5774(I) (where: X1 and X2 are independently a single bond, a substituted or unsubstituted alkylene, one or more -C Alkylene separated by (=O)O-, one or more -OC(=O)- Separated alkylene, alkylene separated by one or more -C(=O)NH- are selected from The X3 is JPEG2024543655000004.jpg1517, JPEG2024543655000005.jpg2017, JPEG2024543655000006.jpg1517, Selected from JPEG2024543655000007.jpg1517, R1 is selected from H, alkyl, and cycloalkyl; R2 is selected from OH, alkoxy; n is an integer from 1 to 5 (e.g., 1, 2, 3, 4, 5), R3 is H, Selected from JPEG2024543655000008.jpg2445, Here, X4 and X5 are independently a single bond, a substituted or unsubstituted alkylene, one or more Alkylene separated by a number of -C(=O)O-, one or more -OC(=O)- alkylene separated by one or more -C(=O)NH- alkylene; The X6 is JPEG2024543655000009.jpg1517, JPEG2024543655000010.jpg2017, JPEG2024543655000011.jpg1517, Selected from JPEG2024543655000012.jpg1517, R4 is selected from H, alkyl, and cycloalkyl; R5 is selected from OH, alkoxy; m is an integer from 1 to 5 (e.g., 1, 2, 3, 4, 5).
[0007] Specifically, X1 is a single bond, a C1-6 linear or branched alkylene, particularly a C1-3 linear alkylene. alkyl, in one embodiment of the present invention, X1 is methylene.
[0008] In one embodiment of the present invention, X2 has the structure JPEG2024543655000013.jpg1817, where R7 is H, alkyl, alkyl substituted with alkylmercapto, hyaluronan, Hydroxy-substituted alkyl, mercapto-substituted alkyl, -C(=O)NH2 alkyl substituted with , alkyl substituted with carboxy, alkyl substituted with amino , JPEG2024543655000014.jpg2128 is selected from alkyl, heterocyclylalkyl, alkyl, and aralkyl substituted with.
[0009] Specifically, R7 is H, methyl, isopropyl, sec-butyl, isobutyl, JPEG2024543655000015.jpg1027, JPEG2024543655000016.jpg920, JPEG2024543655000017.jpg920, JPEG2024543655000018.jpg1615, JPEG2024543655000019.jpg1834, JPEG2024543655000020.jpg1828, JPEG2024543655000021.jpg927, JPEG2024543655000022.jpg934, JPEG2024543655000023.jpg1040, JPEG2024543655000024.jpg2146, JPEG2024543655000025.jpg1727, JPEG2024543655000026.jpg1938, JPEG2024543655000027.jpg2439, JPEG2024543655000028.jpg1531, and in one embodiment of the present invention, R7 is JPEG2024543655000029.jpg1027.
[0010] In some embodiments of the present invention, X3 is The image is JPEG2024543655000030.jpg1517.
[0011] In some embodiments of the present invention, n is 1. In some embodiments of the present invention, R1 is H.
[0012] Specifically, R2 is selected from OH, C1-6 alkoxy, and in some embodiments of the present invention In examples, R2 is OH, methoxy or ethoxy.
[0013] In one embodiment of the invention, the compound has the structure: JPEG2024543655000031.jpg5367(II)
[0014] More specifically, the compound has the following structure: JPEG2024543655000032.jpg5366(III)
[0015] In one embodiment of the present invention, R3 is H.
[0016] In another embodiment of the present invention, R3 is The image is JPEG2024543655000033.jpg2445.
[0017] Specifically, X4 is a single bond, a C1-6 linear or branched alkylene, particularly a C1-3 linear alkyl, and in one embodiment of the present invention, X4 is methylene.
[0018] In one embodiment of the present invention, X5 is represented by the structure JPEG2024543655000034.jpg1817, where R8 is H, alkyl, alkyl substituted with alkylmercapto, hyd Hydroxy-substituted alkyl, mercapto-substituted alkyl, -C(=O)NH2 alkyl substituted with , alkyl substituted with carboxy, alkyl substituted with amino , JPEG2024543655000035.jpg2128 is selected from alkyl, heterocyclylalkyl, alkyl, and aralkyl substituted with.
[0019] Specifically, R8 is H, methyl, isopropyl, sec-butyl, isobutyl, JPEG2024543655000036.jpg1027, JPEG2024543655000037.jpg920, JPEG2024543655000038.jpg920, JPEG2024543655000039.jpg1615, JPEG2024543655000040.jpg1834, JPEG2024543655000041.jpg1828, JPEG2024543655000042.jpg927, JPEG2024543655000043.jpg934, JPEG2024543655000044.jpg1040, JPEG2024543655000045.jpg2146, JPEG2024543655000046.jpg1727, JPEG2024543655000047.jpg1938, JPEG2024543655000048.jpg2439, JPEG2024543655000049.jpg1531, and in one embodiment of the present invention, R8 is JPEG2024543655000050.jpg1027.
[0020] In some embodiments of the present invention, X6 is The image is JPEG2024543655000051.jpg1517.
[0021] In some embodiments of the present invention, m is 1.
[0022] In some embodiments of the present invention, R4 is H.
[0023] Specifically, R5 is selected from OH, C1-6 alkoxy, and in some embodiments of the present invention In examples, R5 is OH, methoxy or ethoxy.
[0024] In one embodiment of the present invention, the compound has the following structure: JPEG2024543655000052.jpg5771(IV)
[0025] In another embodiment of the invention, the compound has the following structure: JPEG2024543655000053.jpg5788(V)
[0026] In some embodiments of the present invention, the compound has the following structure: JPEG2024543655000054.jpg5969JPEG2024543655000055.jpg5769JPEG2024543655000056.jpg6383JPEG2024543655000057.jpg6282
[0027] In a second aspect of the present invention, there is provided a stereoisomer of the compound according to the first aspect having the structure do. JPEG2024543655000058.jpg5774(VI)
[0028] where X1, X2, X3, R1, R2, R3, n have the corresponding definitions as described in the first aspect. do.
[0029] In some embodiments of the invention, the stereoisomer has the following structure: JPEG2024543655000059.jpg5769JPEG2024543655000060.jpg6688
[0030] In a third aspect of the present invention, there is provided a compound according to the first aspect or a salt of a stereoisomer according to the second aspect, In particular, pharma- ceutically acceptable salts are provided.
[0031] In particular, the salts are base addition salts, and are salts of metal or amine compounds, in particular base metal salts, salts It may be formed of a base earth metal salt, for example a sodium salt, a potassium salt, a magnesium salt, It is a calcium salt.
[0032] In some embodiments of the invention, the salt is JPEG2024543655000061.jpg5365, or The image is JPEG2024543655000062.jpg6181.
[0033] In a fourth aspect of the present invention, there is provided an ester, prodrug or solvate of a compound according to the first aspect. provide.
[0034] In a fifth aspect of the present invention, there is provided a method for preparing a compound according to the first aspect.
[0035] In one embodiment of the present invention, R3 is H, and the preparation method comprises the following reaction steps: Good too. JPEG2024543655000063.jpg40121
[0036] Here, R2' is alkoxy, for example C1-6 alkoxy, such as methoxy.
[0037] In some embodiments of the present invention, in the reacting step JPEG2024543655000064.jpg2238 is The image is JPEG2024543655000065.jpg3829.
[0038] Specifically, the production method may further include the following reaction steps: JPEG2024543655000066.jpg61119
[0039] Specifically, the base in the reaction step is a hydroxide of a base metal, e.g., hydroxide Lithium, sodium hydroxide, and potassium hydroxide.
[0040] Specifically, the acid in the above reaction step is an inorganic acid such as hydrochloric acid.
[0041] Specifically, the preparation method may further include the following reaction steps: JPEG2024543655000067.jpg56157
[0042] Here, R9 is alkyl, for example, C1-6 alkyl, for example, methyl. R 10 is a leaving group, e.g., -F, -Cl, -Br, -I, JPEG2024543655000068.jpg2748(- OTs), JPEG2024543655000069.jpg1527(-OMs), JPEG2024543655000070.jpg2238(-OBs), (-OTf).
[0043] In some embodiments of the present invention, in the reacting step JPEG2024543655000071.jpg1736 is The image is JPEG2024543655000072.jpg1731.
[0044] Specifically, the base in the reaction step is a hydroxide of a base metal, for example hydroxide The hydroxides are lithium hydroxide, sodium hydroxide, and potassium hydroxide.
[0045] Specifically, the acid in the above reaction step is an inorganic acid such as hydrochloric acid.
[0046] In another embodiment of the present invention, R3 is JPEG2024543655000073.jpg2445, and this manufacturing method is JPEG2024543655000074.jpg4846, respectively or simultaneously (in this case representing the same thing) JPEG2024543655000075.jpg2238, The method may include reacting with JPEG2024543655000076.jpg2238.
[0047] Here, R2' and R5' are alkoxy, for example, C1-6 alkoxy, for example, methoxy. do.
[0048] In an embodiment of the present invention, JPEG2024543655000077.jpg2238 and JPEG2024543655000078.jpg2238 represents the same thing, for example: The image is JPEG2024543655000079.jpg3829.
[0049] In a sixth aspect of the invention, there is provided a compound according to the first aspect of the invention, or a pharma- ceutically acceptable derivative thereof. Salts, stereoisomers, esters, prodrugs, solvates, and one or more pharma- ceutically acceptable salts, and ancillary materials as described above.
[0050] Specifically, the pharma- ceutically acceptable auxiliary materials include fillers, adhesives, lubricants, disintegrants, antioxidants, etc. One selected from the group consisting of agents, buffers, suspension aids, solubilizers, thickeners, stabilizers, and preservatives. Or it may be a plurality of types.
[0051] In particular, the pharmaceutical composition can be administered gastrointestinally or intravenously, for example, intramuscularly, intradermally and transdermally. The drug may be administered parenterally, such as via the intravenous route.
[0052] Specifically, the pharmaceutical composition may be in the form of a tablet, a pill, a powder, a granule, a capsule, a lozenge, Syrups, gels, emulsions, suspensions, controlled release preparations, aerosols, films, injections , drops, transdermal agents, ointments, lotions, patches, suppositories, nasal drops, pulmonary preparations, etc. It can be formulated into a dosage form.
[0053] Specifically, the various dosage forms of the above pharmaceutical compositions can be prepared by a method commonly used in the pharmaceutical field. can.
[0054] In particular, the pharmaceutical composition may comprise one or more other active agents for the same or a different indication. It may also contain a sexual component.
[0055] In a seventh aspect of the invention, there is provided a method for the preparation of a medicament for preventing and / or treating a disease comprising the steps of: The compound according to one embodiment, or a pharma- ceutically acceptable salt, stereoisomer, ester, prodrug thereof, The present invention provides a pharmaceutical composition according to the sixth aspect,
[0056] Specifically, the above diseases include nervous system diseases, cancer, autoimmune diseases, cardiovascular diseases, pain, and inflammation. , liver damage, and in particular nervous system diseases.
[0057] Specifically, neurological diseases include epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. including, but not limited to, dementia with Lewy bodies, Huntington's disease, anxiety, and depression. I can't.
[0058] In particular, the epilepsy may be acute epilepsy, chronic epilepsy, especially chronic epilepsy. stomach.
[0059] Specifically, the cancers are breast cancer, lung cancer, colorectal cancer, liver cancer, pancreatic cancer, gastric cancer, and Esophageal adenocarcinoma, esophageal cancer, small intestine cancer, cardia cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, vulvar cancer Cancer, including but not limited to, testicular cancer, prostate cancer, leukemia, glioma, etc.
[0060] Specifically, autoimmune diseases include systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, These include, but are not limited to, ulcerative colitis, Crohn's disease, autoimmune hepatitis, and the like.
[0061] In an eighth aspect of the present invention, a compound according to the first aspect of the present invention, or a pharma- ceutically acceptable derivative thereof is provided. A salt, stereoisomer, ester, prodrug, solvate or pharmaceutical composition according to the sixth aspect. A method for preventing and / or treating a disease, comprising administering to a subject in need thereof to provide.
[0062] Specifically, the above diseases include nervous system diseases, cancer, autoimmune diseases, cardiovascular diseases, pain, and inflammation. , liver damage, and in particular nervous system diseases.
[0063] Specifically, neurological diseases include epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease. including, but not limited to, dementia with Lewy bodies, Huntington's disease, anxiety, and depression. I can't.
[0064] In particular, the epilepsy may be acute epilepsy, chronic epilepsy, especially chronic epilepsy. stomach.
[0065] Specifically, the cancers are breast cancer, lung cancer, colorectal cancer, liver cancer, pancreatic cancer, gastric cancer, and Esophageal adenocarcinoma, esophageal cancer, small intestine cancer, cardia cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, vulvar cancer Cancer, including but not limited to, testicular cancer, prostate cancer, leukemia, glioma, etc.
[0066] Specifically, autoimmune diseases include systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, These include, but are not limited to, ulcerative colitis, Crohn's disease, autoimmune hepatitis, and the like.
[0067] Specifically, the subject may be a mammal, such as a human, an orangutan, a monkey, a dog, a rabbit, It may be a rodent or the like, and particularly a human.
[0068] The inventors of the present invention have carried out structural modifications based on cannabidiol to produce a series of synthetic derivatives. The compounds of the present invention were obtained by screening against the above compounds. Effectively shorten the duration of epileptic seizures in experimental animals and improve the symptoms of epileptic seizures in experimental animals. It also reduced balance beam scores in Parkinson's disease model animals and increased dopamine levels. and improves the positive rate of tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain. This can be used in the research and development of drugs for various diseases such as epilepsy and Parkinson's disease. It is useful and has high application value. [Brief description of the drawings]
[0069] [Figure 1] 1 shows the detection results of seizure duration before and after treatment of PTZ-induced epilepsy rats. [Diagram 2] Ono's grades of behavioral seizure indices of PTZ-induced epileptic rats before and after treatment are shown. [Diagram 3] The results of seizure latency detection before and after treatment of PTZ-induced epilepsy rats are shown. [Figure 4] 1 shows a PAGE gel image of apoptosis-related proteins Bax and Bcl-2 in rat hippocampal tissue. [Diagram 5] 1 shows changes in apoptosis-related proteins Bax and Bcl-2 in rat hippocampal tissue. [Figure 6]1 shows the results of detecting γ-aminobutyric acid content in rat brain tissue homogenates. [Figure 7] 1 shows the results of detecting glycine content in rat brain tissue homogenates. [Figure 8] 1 shows the results of detecting glutamic acid content in rat brain tissue homogenates. [Figure 9] 1 shows the results of detecting aspartic acid content in rat brain tissue homogenates. [Figure 10] 1 shows the behavioral balance beam score results of a Parkinson's disease model. [Figure 11] 1 shows the results of detecting dopamine content in the striatum after treatment of a Parkinson's disease model. [Figure 12] The positive rate of tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain is shown. [Figure 13] Shown is a microscopic image of tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0070] Unless otherwise defined, all scientific and technical terms used herein are understood by those of ordinary skill in the art. It has the same meaning as commonly understood.
[0071] The term "alkyl" refers to a hydrocarbon group in which an alkane molecule has lost one hydrogen atom. It may be straight or branched and is attached to the rest of the molecule by a single bond. The alkyl group is generally 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) carbon atoms, preferably 1 to 6 carbon atoms (i.e., C1 to C 6 alkyl). Examples of the alkyl include methyl, ethyl, n-propyl, isopropyl, and ethyl. Propyl, n-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl Examples include, but are not limited to, butyl, t-pentyl, n-hexyl, and isohexyl. When an alkyl is substituted with an aryl, it is not considered an "aralkyl" (e.g., C7~C 18 Aralkyl, e.g. C7~C 15 Aralkyl, C7~C 12 Aralkyl, e.g. For example, (C1-C6 alkylene)-(C6-C 12 Aryl), (C1-C3 alkylene )-phenyl), for example, benzyl, diphenylmethyl, or phenylethyl. When alkyl is substituted with heterocyclyl, it is a "heterocyclylalkyl." do.
[0072] The term "alkylene" refers to a hydrocarbon group in which an alkane molecule has lost two hydrogen atoms (a divalent (alkyl) and is a straight or branched chain that is connected to the rest of the molecule by a single bond. Here, typical alkylene groups are those having 1 to 12 carbon atoms (e.g., 1, 2, 3, 4 , 5, 6, 7, 8, 9, 10, 11, 12), preferably 1 to 6 carbon atoms, Examples of alkylenes are methylene (-CH2-), ethylene, propylene, and butylene. .
[0073] The term "alkoxy" refers to a substituent in which the hydrogen in a hydroxyl group is replaced with an alkyl group. As used herein, alkoxy generally refers to an alkyl group having an alkyl group of 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) carbon atoms, preferably 1 to 6 carbon atoms (i.e., C1 to C6 alkoxy). The alkoxy includes methoxy, ethoxy, and the like. Examples of alkoxy include, but are not limited to, oxy, propoxy, butoxy and the like.
[0074] The term "cycloalkyl" includes, for example, 1 to 4 single and / or fused rings, 3 to 18 carbon atoms, preferably 3 to 10 (e.g., 3, 4, 5, 6, 7, 8, 9, 10 ) carbon atoms, e.g., cyclopropyl, cyclobutyl, For example, cyclopentyl, cyclohexyl, or adamantyl.
[0075] The term "aryl" refers to a functional group or substituent derived from a simple aromatic ring. ~ 3 rings and / or fused rings with 6 to 18 (e.g., 6, 8, 10, 12, 1 aryl groups and / or fused ring aryl groups having 4, 16, or 18) carbon ring atoms. As used herein, aryl generally refers to a single ring or fused ring system containing 1 to 2 rings and 6 to 10 rings. Aryl having 12 carbon ring atoms (i.e., C6-C 12 aryl), and carbon The H on the atom may be substituted, for example with alkyl, halogen, or other groups. Examples of the aryl include phenyl and p-hydroxyphenyl. Includes, but is not limited to:
[0076] The term "heterocyclyl" refers to a group containing 2 to 17 carbon atoms and 1 to 10 heteroatoms. Heterocyclyl refers to a fused, spiro, or bridged ring system. The heterocyclyl may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include It may be a partially saturated (heteroaryl) group or a fully saturated (heterocyclo) group. It may be a (methoxyalkyl) group.
[0077] The term "pharmaceutically acceptable salt" includes acid addition salts and base addition salts.
[0078] The term "stereoisomers" refers to the forms of enantiomers, diastereomers, and geometric isomers. This includes those that exist in
[0079] The term "solvate" refers to a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In some cases, a solvate can be formed, for example, by dissolving one or more solvent molecules in the crystalline solid state. The solvate may be separated from the solution phase when incorporated into the polymer. Representative solvates include ethanolates, methanolates, and the like.
[0080] The term "prodrug" refers to a drug that is effective in treating a patient without excessive toxicity, irritation, allergic reactions, etc. Acetals, esters and zwitterions suitable for administration to a subject and effective for their intended purpose. Prodrugs refer to forms of the compounds of formula I, including the form This results in in vivo conversion to the parent compound.
[0081] The term "subject" is used herein whether in vitro or in situ. The term "animal" refers to any animal or cell thereof that is amenable to the methods described above. an animal, such as a rat, a mouse, a guinea pig, a rabbit, a dog, a monkey, an orangutan, or Humans, particularly humans, are included.
[0082] The term "treatment" refers to the prevention, cure or amelioration of one or more clinical symptoms of a disease after onset of the disease. It refers to curing, reversing, mitigating, alleviating, minimizing, suppressing, preventing, and / or stopping.
[0083] The term "prevention" refers to avoiding, minimizing, or preventing the onset or progression of a disease before the onset of the disease. refers to performing a treatment to make something more difficult.
[0084] The disclosures of various publications, patents, and published patent specifications cited herein are hereby incorporated by reference in their entirety. The body is incorporated by reference.
[0085] The following describes the technical solutions of the present invention clearly and completely with reference to the embodiments of the present invention. However, the described embodiments are merely a part of the embodiments of the present invention, and are not all of the embodiments. It is obvious that the invention can be obtained by a person skilled in the art without any creative work based on the embodiments of the present invention. All of the above embodiments are within the scope of protection of the present invention. Example 1: Preparation of compound E1 JPEG2024543655000080.jpg5263
[0086] 1.Synthetic Scheme JPEG2024543655000081.jpg82132
[0087] 2.Synthesis method
[0088] (1) Synthesis of Compound 2 JPEG2024543655000082.jpg61147
[0089] Testing Procedure: CBD (20 g, 64 mmol, 1 eq) was dissolved in 400 ml of butanone and cesium carbonate was added. (31g, 96mmol, 1.5eq) was added, and the mixture was heated to 80°C and reacted for 2h. 12.6 g (0.082 mol, 1.3 eq) of methylbromoacetate was added and reacted overnight. Methyl bromoacetate (5 g) and cesium carbonate (15 g) were added and the reaction was allowed to proceed for 2 hours. The liquid was filtered and concentrated, then ethyl acetate (100 ml) was added, washed with 2N hydrochloric acid, and saturated sodium chloride was added. The organic phase was collected, dried over anhydrous sodium sulfate, and concentrated to a brown oil. A crude product (30 g) was obtained. Column chromatography (n-hexane / dichloromethane 20 Compound 1 (11 g) and Compound 5 (10.5 g) were obtained as yellow oils. Ta. Compound 1 (11 g, 28.5 mmol, 1 eq) was dissolved in THF (100 ml) and diluted with hydroxyl. Lithium chloride (3.6 g, 85 mmol, 3 eq) was dissolved in 15 ml of water and stirred overnight. Stirred. Adjust the pH to 3-4 with 2N dilute hydrochloric acid, add ethyl acetate (300 ml), separate the layers, and The resulting phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated and dried over yellow water. Compound 2 (9.5 g) was obtained as a colored oil and used directly in the next step.
[0090] (2) Synthesis of Compound 3 JPEG2024543655000083.jpg53156
[0091] Testing Procedure: Compound 2 (9.5 g, 24.6 mmol, 1 eq), methionine methyl ester hydrochloride ( 6.4g, 32mol, 1.3eq), and DMAP (4.5g, 37mol, 1.5e q) was dissolved in dichloromethane (60 ml) and DCC (7.6 g, 37 mmol, 1.5 eq) was added and stirred at room temperature overnight. The reaction mixture was filtered, the filter cake was washed with 50 ml of dichloromethane, and the filtrate was washed with 2N hydrochloric acid. The crude product was extracted with 1,000 ml of ethyl acetate, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated. The product was purified by column chromatography (n-hexane / dichloromethane: 5 / 1-1 / 1, n- Compound 3 was extracted with hexane / dichloromethane / ethyl acetate (1 / 1 / 0.1) to give a yellow oil. (6.6g) was obtained.
[0092] (3) Synthesis of compound 4 (free acid) JPEG2024543655000084.jpg55152
[0093] Testing Procedure: 6.6 g (0.0128 mol, 1 eq) of compound 3 was dissolved in 80 ml of THF. Dissolve 6g (0.0383mol, 3eq) of lithium hydroxide in 10ml of water and add to the reaction solution. The mixture was then reacted at room temperature overnight. The reaction mixture was concentrated, 100 ml of ethyl acetate was added, the pH was adjusted to 2 with 2N hydrochloric acid, and the liquids were separated. The organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered and concentrated. The crude product was purified by column chromatography (dichloromethane / methanol). The mixture was subjected to elution using a solvent mixture ratio of 150 / 1 to 50 / 1 to give compound 4 (3.4 g) as a yellow oil.
[0094] (4) Synthesis of compound E1 (sodium salt) JPEG2024543655000085.jpg54166
[0095] Testing Procedure: Compound 4 (3.4 g, 6.8 mmol, 1 eq) was dissolved in 20 ml of ethanol and diluted with carbonated water. Dissolve sodium chloride (0.625 g, 7.4 mmol, 1.1 eq) in 10 ml of water and mix. The mixture was mixed, stirred, heated to 50°C, and reacted for 1 hour. The reaction mixture was concentrated, 30 ml of ethanol was added, and the mixture was evaporated to dryness. The residue was dissolved in n-hexafluoropropane. The mixture was washed with a mixed solvent of 60 ml of ethanol and 20 ml of dichloromethane, dried, and a powdery solid E1 ( 2.4 g) was obtained. HPLC>98%. MS(ESI, positive): 504.1[M+H]+ . 1 H-NMR(400MHz, CD3OD): 6.30(d, J=0.8Hz, 1H), 6.20(s, 1H), 5.29(s, 1H), 4.55-4.36 (m, 5H), 4.03-4.05(m, 1H), 2.97-2.91(m, 1H), 2.46(t, J=7.6Hz, 2H), 2.42-2.36(m, 2H), 2.26-2.16(m, 2H), 2.05(s, 3H), 2.04- 1.91(m, 2H), 1.80-1.74(m, 2H), 1.63(s, 3) H), 1.561(s, 3H), 1.61-1.53(m, 2H), 1.37 -1.32(m, 4H), 0.90(t, J=6.8Hz, 3H). The detection results show that the solubility of compound E1 in water reaches 2.7g / 100ml water.
[0096] Example 2: Synthesis of Compound E2 JPEG2024543655000086.jpg5877
[0097] 1.Synthetic Scheme JPEG2024543655000087.jpg124124
[0098] 2.Synthesis method
[0099] (1) Synthesis of compound 6 Compound 5 (10.5 g, 0.0229 mol, prepared in Example 1) was dissolved in 100 mL of methanol. Dissolve in, add potassium hydroxide (3.8 g, 0.0688 mol), stir and heat. The reaction mixture was concentrated, and the residue was washed with 100 ml of ethyl acetate and filtered. The filter cake was washed with 200 ml of ethyl acetate, adjusted to pH 2 with 2N dilute hydrochloric acid, and separated. The organic phase was washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and concentrated. Condensation gave yellow oily compound 6 (9 g). MS(ESI);431 [M+H] +
[0100] (2) Synthesis of compound 7 JPEG2024543655000088.jpg72156 Compound 6 (6.3 g, 0.0145 mol), methionine methyl ester hydrochloride (11. 7g, 0.0586mol), DMAP (7.15g, 0.0586mol) Dissolve in 200 ml of methane, add DCC (12 g, 0.0586 mmol), and stir at room temperature. The reaction was allowed to proceed overnight. The reaction mixture was filtered, and the filter cake was washed with 50 ml of dichloromethane. The mixture was washed with 2N hydrochloric acid and saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated. After condensation, the mixture was subjected to column chromatography (n-hexane:dichloromethane=5:1-1:1, n -Hexane:dichloromethane:ethyl acetate=1;1:0.1) to give yellow oily compound 7 (6g) was obtained. MS(ESI): 721 [M+H] +
[0101] (3) Synthesis of compound 8 JPEG2024543655000089.jpg44129Compound 7 (10 g, 0.014 mol, 1 eq) was dissolved in 80 ml of THF and added with Add 8 ml of a solution of tium (1.7 g, 0.042 mol, 3 eq) and react overnight at room temperature. The reaction mixture was concentrated, 100 ml of ethanol was added, and the mixture was evaporated to dryness once. Wash with hexane, concentrate, add 100 ml of ethyl acetate, and adjust pH to 2 with 2N hydrochloric acid. The mixture was separated, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and concentrated to give Yellow solid compound 8 (10 g) was obtained. MS(ESI):693 [M+H] +
[0102] (4) Synthesis of compound E2 JPEG2024543655000090.jpg45132Compound 8 (10 g, 0.0144 mol) was dissolved in 80 ml of ethanol and sodium bicarbonate was added. Dissolve sodium (2.5 g, 0.0304 mol, 2.1 mol) in 20 ml of water and mix. The mixture was stirred at 50°C for 1 hour. The reaction mixture was concentrated, 100 ml of ethanol was added, and Evaporate to dryness, wash the residue with 20 ml of dichloromethane and dry to give a nearly white solid, E Obtained 2 (8.1 g). MS (ESI): 693 [M+H] + ; 1 H-NMR (CD 3OD): 6.48(s,2H),5.32(s,1H),4.62-4.55 (m,4H), 4.44-4.39(m,4H),4.13-4.18(m,1H), 4.15((d,1H) ,3.01-2.95 (m,1H) ,2.58-2.5 4(t,2H),2.42-2.38(t.4H),2.17-2.19(m,2H) ,2.03(s,6H), 1.99-1.95 (m,3H), 1.84-1.81 (t,2H) ,1.72(s,3H), 1.66(s,3H), 1.64-1.6 0(m,2H) ,1.39-1.33(m,4H) ,0.94-0.91 (t,3 H) The results show that the solubility of compound E2 in water reaches 20g / 100ml water.
[0103] Example 3: Antiepileptic activity studies
[0104] 1. Experimental animals and some reagents Wistar rat, SPF grade, weight 240-260g, age 6-8 weeks, female, The animals were purchased from Histellique Laboratory Animal Co., Ltd. The temperature and humidity in the rearing environment were 22±1℃ and 100%. The light / dark cycle was 65-70%, 12 hours, and water was available ad libitum. PTZ was purchased from Sigma, and sodium valproate was purchased from Sigma. Absolute ethanol was purchased from China Pharmaceutical Group Chemical Reagents Co., Ltd.
[0105] 2. Experimental Grouping The experimental animals were randomly divided into four groups of eight animals each: model group, positive drug group, compound group 1, and compound group 2. It was divided into.
[0106] 3. Experimental Method (1) Modeling by intraperitoneal injection All rats were reared for 1 week for adaptation and then started modeling. 1. A 75% PTZ solution was freshly prepared and the prepared PTZ solution was injected intraperitoneally at a dose of 35 mg / kg. PTZ was injected into the rats every other day, and behavioral changes in the rats were evaluated within 30 min after PTZ injection. Changes were observed and the severity of the attacks was recorded. During the experiment, PTZ was injected 11 times in succession, and the severity of the seizures was recorded. All rat models had 5 consecutive records of grade 2 or higher and received 11 consecutive injections of PZT. The shot was successful.
[0107] (2) Intragastric administration Once modeling was successful, the groups were randomized. Treatment was started and all Wistar rats were The body weight of each rat was measured, and the amount of intragastric administration was calculated. The model group received an equal volume of saline intragastric administration. The positive drug group was administered sodium valproate at 100 mg / kg intragastrically, and the compound group 1 was administered Compound E1 prepared in Example 1 was intragastrically administered at 100 mg / kg. Compound group 2 was administered in Example 1. Compound E2 prepared in 2 was intragastrically administered at 100 mg / kg.
[0108] (3)Ono's grade Before administration, and on the 7th and 14th days after administration, the prepared PTZ solution was administered intragastrically and then 35 min The rats were injected intraperitoneally at a dose of 1000 mg / kg. The behavioral changes of rats within 30 min after PTZ injection were was observed.
[0109] Behavioral seizure indices before and after administration were recorded according to Ono's scale, and seizure latency, seizure grade, and onset were recorded. The duration of action was recorded.
[0110] Table 1 Ono's grade JPEG2024543655000091.jpg199140
[0111] After the experiment was completed, the brains and hippocampi of the experimental animals were collected and frozen at -80°C.
[0112] 4. WB was used to detect the expression of apoptosis-related proteins Bax and Bcl-2 in rat hippocampal tissue. Expression was detected.
[0113] 4.1 Reagents, Antibodies and Equipment Some of the reagents, antibodies, and equipment used in the experiments are shown in Tables 2 to 4.
[0114] Table 2 Reagents JPEG2024543655000092.jpg199140
[0115] Table 3 Antibodies JPEG2024543655000093.jpg199140
[0116] Table 4 Equipment JPEG2024543655000094.jpg199140
[0117] 4.2 Sample preparation Cut the hippocampal tissue into small pieces and add lysis solution at a ratio of 150-250 μl per 20 mg of tissue ( Protease and phosphatase inhibitors were added to the lysis solution, and the mixture was homogenized until completely dissolved. The lysed sample was centrifuged at 12000g for 15 minutes at 4°C. The supernatant was collected, protein quantified, and stored in a refrigerator at -80°C.
[0118] 4.3 Protein quantification (1) Preparation of standard curve: Prepare one plate and add reagents according to the table below.
[0119] Table 5. Reagents JPEG2024543655000095.jpg199140(2) Depending on the number of samples, mix BCA Reagent A and Reagent B in a volume ratio of 50:1 to prepare an appropriate A volume of BCA working solution was prepared and mixed thoroughly. (3) 160 μl of BCA working solution was added to each well. (4) Place the plate on an oscillator, shake for 30 seconds, and then leave it at 37°C for 30 minutes. The absorbance at 562 nm was measured. The horizontal axis represents absorbance, and the vertical axis represents protein concentration (μg / μl). was used to prepare a standard curve. (5) Add 2 μl of the test protein and 18 μl of PBS (10-fold dilution) to the plate. Add 160 μl of BCA working solution, place the plate on an oscillator, shake for 30 sec, and The mixture was allowed to stand at 7° C. for 30 minutes, after which the absorbance at 562 nm was measured. (6) Based on the absorbance value of the measured sample, the corresponding protein concentration on the standard curve is calculated. (μg / μl) and multiplying this by the sample dilution factor (10) gives the actual concentration of the sample. The concentration (unit: μg / μl) was obtained.
[0120] 4.4 Loading and electrophoresis
[0121] (1) Loading The loading amount per well was approximately 25 μg of protein, and the loading amount was determined experimentally. Depending on the protein quantification results, the required protein may be increased. Add an appropriate amount of loading buffer, heat in a boiling bath for 10 minutes, and then centrifuge to remove the supernatant. The prepared PAGE gel was placed in an electrophoresis tank and an appropriate amount of electrophoresis supernatant was added. Add buffer, remove comb, and remove any excess in the wells that may affect sample loading. The sample wells were gently pipetted with the gun to avoid excess gel residue. The prepared sample is then poured into the sampling gun so that it does not overflow from the sample injection well. The solution was slowly added to the wells.
[0122] (2) Electrophoresis Generally, stacking gels are run at 80V for 20 minutes, and separating gels at 120V for 6 minutes. The voltage and time may be adjusted depending on the specific experimental requirements. Once this is reached, the power is turned off, stopping the electrophoresis and proceeding to the next transfer step.
[0123] Transcription There are two types of transfer: wet transfer and semi-dry transfer. In this experiment, we chose semi-dry transfer. Ta. For semi-dry transfer, a sandwich arrangement of gel / membrane / filter paper was used. After soaking in the microporation buffer, place the gel on the negative electrode and the membrane on the positive electrode. The plate was placed directly between the positive and negative electrodes of the electroporation device. Unlike wet electroporation buffer, 8 mM Tris, 39 mM glycine, 0.04% SDS, and 20% methanol. The transfer was performed at 25 V for 30 minutes. Before the transfer, the PVDF membrane was washed with methanol. (NC membrane is soaked in electroporation solution for 10 to 20 minutes. The gel was then incubated in ice-cold electroporation buffer for 5 minutes. All plates must be equilibrated with ice-cold electroporation buffer for 3–5 min. Otherwise, the band will deform during transfer. Detection of proteins on membranes To test whether the transfer was successful, Ponceau Red staining was used. The working solution for staining was a 1:10 dilution of Ponceau stock solution, i.e. 9 times ddH2 It is the addition of O.
[0124] Staining method: Wash the membrane once with TBST, place it in Ponceau Red staining solution, and incubate at room temperature. Stain at 4°C for 5 min with shaking until the water becomes clear and colorless protein bands become evident. The membrane was washed with copious amounts of water (before staining, the membrane was washed again with TBST or water). (You can also reactivate the PVDF membrane with methanol and then wash it with TBST.) and block.
[0125] 4.5 Membrane blocking and antibody incubation (1) Block: 5% skim milk powder (BSA for detecting phosphorylated proteins) at room temperature for 1 hour, or was blocked overnight at 4°C. (2) Primary antibody: Instructions Bcl-2 1:500 Bax 1:5000 GAPD Dilute the antibody according to H 1:30000 and add the antibody to the blocking solution to the required concentration. The mixture was incubated with the membrane for 2 hours at room temperature and then overnight at 4°C. (3) Secondary antibody: The membrane incubated with the primary antibody is incubated in TBST for 5 min each. After washing three times, the secondary antibody was diluted with HRP at a ratio of 1:1000 depending on the volume. The plate was incubated with the membrane at 37°C for 1 h. The plate was then washed three times with TBST for 5 min each. Purified.
[0126] 4.6 Color development ECL chemiluminescence detection: Prepare ECL luminescence solution and mix ECL luminescence solution A and B according to the amount to be used. A small amount was taken, mixed uniformly, and added to the front of the membrane, and left to stand for 5 minutes in a dark room away from light. The coloring liquid was discarded, the coloring liquid was carefully absorbed with paper, and then a flat transparent paper was placed on top of it. It was then placed into a processing system and scanned.
[0127] 5. The contents of γ-aminobutyric acid, glutamic acid, glycine, and aspartic acid in rat brain tissue Kit method for detecting the amount
[0128] 5.1 Experimental materials The kits and equipment used in the experiment are shown in the table below.
[0129] Table 6. Kit Information JPEG2024543655000096.jpg199140
[0130] Table 7. Major equipment and consumables JPEG2024543655000097.jpg199140
[0131] 5.2 Experimental Method For experimental procedures and methods, refer to the kit instructions.
[0132] 6. Experimental Results
[0133] (1) The duration of epileptic seizures before and after treatment in PTZ-induced epileptic rats is shown in the following table and Figure 1. show.
[0134] Table 8. Seizure duration before and after treatment in PTZ-induced epileptic rats JPEG2024543655000098.jpg199140
[0135] As a result, when comparing the data on the duration of PTZ-induced epilepsy before and after treatment, The duration of each group was almost the same, with the duration of the attack being about 350 seconds, but the duration of each group was The difference between the two groups became clear, and when the treatment phase began, the positive drug group showed a significant difference on the 7th and 14th days of treatment. Seizure duration was reduced, which was statistically significant, at 7 days post-treatment in the other compound groups. The seizure duration was statistically significantly reduced compared to before treatment. 2, seizure duration was longer on the 14th day of treatment compared with seizure duration on the 7th day of treatment. Compound 1 showed a statistically significant decrease in the duration of AF on the 14th day of treatment and on the 7th day of treatment. When comparing seizure duration with Compound 1, there was no change in seizure duration.
[0136] (2) The Ono's scale of behavioral seizure index of PTZ-induced epileptic rats before and after treatment is shown in the table below. This is shown in Figure 2.
[0137] Table 9. Ono's grades of behavioral seizure indices in PTZ-induced epileptic rats before and after treatment JPEG2024543655000099.jpg199140
[0138] As a result, the behavioral seizure index before and after treatment was recorded according to Ono's scale. After the completion of the study and during treatment, if epilepsy was induced by injection of PTZ, The no's grades were all 3 to 4, with no significant difference between the groups. There were no significant differences between the groups.
[0139] During the experiment, the Ono's scale records the highest grade of seizures in the rats. Epileptic seizures are a progressive process, and the highest grade of seizures lasts for the duration of the seizure. Subsequent recording of the duration of each seizure grade is recommended.
[0140] During the experiment, if the Ono's grade was 5-6, most of the rats would die if no measures were taken. Even if the mice died but not the rats, PTZ-induced mortality was also observed in the rats. It was discovered that...
[0141] (3) The seizure latency of PTZ-induced epileptic rats before and after treatment is shown in the table below and Figure 3.
[0142] [Table 10] Seizure latency before and after treatment in PTZ-induced epileptic rats JPEG2024543655000100.jpg199140
[0143] As a result, the latency of PTZ-induced epilepsy seizures before and after treatment was significantly higher than that of PTZ before and during treatment. The average latency of Z-induced epileptic seizures was 80-100 s. The duration of epilepsy induction by PTZ ranged from 60s to 120s. There was a clear correlation between the groups. There was no clear trend for changes in seizure latency over time among the same groups. .
[0144] (4) Changes in apoptosis-related proteins Bax and Bcl-2 in rat hippocampal tissue The results of WB detection are shown in Figures 4 and 5.
[0145] The experimental results showed that the apoptosis-related Bax protein was highly expressed in the hippocampal tissue of the model rats. In contrast, the positive drug group and the model group expressed apoptosis-related Bax protein. Both compound E1 and compound E2 showed low and statistically significant expression. The results showed a clear and significant downregulation of Bax protein expression.
[0146] Anti-apoptotic Bcl-2 protein was detected in the hippocampal tissue of rats from each group. The results showed that the expression of Bcl-2 protein in the model group was significantly lower than that in the other groups, and the Bcl-2 expression in the positive drug group was significantly higher than that in the other groups. The expression of cl-2 protein was higher than in the other groups, and in the compound group, compound E1 and compound E2 In both groups, the expression of Bcl-2 protein was higher than in the model group, and it was found to be statistically significant. showed.
[0147] (5) The concentrations of γ-aminobutyric acid, glutamic acid, glycine, and aspartate in rat brain tissue homogenates were The measurement results of the content of paraginic acid are shown in the table below and in FIGS.
[0148] [Table 11] γ-aminobutyric acid, glutamic acid, and glycine in rat brain tissue homogenates , Aspartic acid content measurement results JPEG2024543655000101.jpg199140
[0149] Excitatory amino acids in brain tissue homogenates: glutamate and aspartate, and inhibitory Neurotransmitters: γ-aminobutyric acid and glycine contents were detected by ELISA detection kit. I put it out.
[0150] The ELISA experiment showed that the brain tissue homogenates from the model group contained gamma-aminobutyric acid and glycine. It was shown that the content of α-amyloides was low and the contents of glutamic acid and aspartic acid were high. Compared with the model group, the positive drug group and the compound group both showed a lower expression of excitatory amino acids. The results were statistically significant. The expression levels of butyric acid and glycine were increased compared to the model group, and were statistically significant.
[0151] 7. Summary of the experiment
[0152] During the treatment of rats in the PTZ-induced rat epilepsy model, the positive drugs and each compound for rats The therapeutic effects of the drugs showed significant differences in the duration of PTZ-induced rat epilepsy, and in the latency and seizure time. There was a tendency for an effect on the degree of the kan model, but the difference was not significant. Compared with the model group, the duration of epilepsy seizures was significantly shorter in the two compound groups at 7 and 14 days after treatment. On the 7th day of treatment, the duration of epileptic seizures was significantly reduced. The order of seizure duration was compound E2 > compound E1, and on the 14th day of treatment, the seizure duration was compound E2 > compound E1. The order was compound E1.
[0153] The apoptosis-related proteins Bax and Bcl-2 in the hippocampal tissue of rats on the 14th day of treatment In the brain tissue homogenate, excitatory amino acids: glutamate and aspartate, and inhibitory Inhibitory neurotransmitters: Compare the content of gamma-aminobutyric acid and glycine.
[0154] Example 4: Treatment study of Parkinson's disease
[0155] 1. Experimental animals and some reagents C57 / BL6 mice, SPF grade, body weight 18-20g, age 6-8 weeks, male, Shanghai Sichuan University The animals were purchased from K.K. Laboratory Animal Co., Ltd. The temperature and humidity in the rearing environment were 22±1℃ and 65~70℃, respectively. %, the light / dark cycle was 12 hours, and water was available ad libitum. MPTP was purchased from Sigma, amantadine was purchased from Sigma, and anhydrous ethanol was Nol was purchased from China National Pharmaceutical Group Chemical Reagents Co., Ltd.
[0156] 2. Experimental Grouping The experimental animals were divided into blank group, model group, positive drug group, compound 1 group, and compound 2 group (8 animals each). They were randomly divided into five groups.
[0157] 3. Experimental Method (1) Purchase 6-8 week-old SPF grade C57 mice, raise them for one week for adaptation, and then transfer them to the mice. The derring-do has begun. (2) MPTP (25 mg / kg) was intraperitoneally injected once a day for 7 consecutive days. was not processed. (3) Once modeling was completed, administration was started. The positive drug group was amantadine (40 mg / kg), and the test substance group (100 mg / kg) were administered once a day at a designated dose for 14 consecutive days. The administration was intragastrically. (4) Behavioral testing first: Balance beam detection score A wooden stick 80 cm long and 2.5 cm wide is fixed horizontally at a height of 10 cm from the table. The animals were allowed to walk on the
[0158] If you can jump onto a balance beam and walk freely without falling over, 0 points, the animal can jump onto the balance beam, but not when walking on it If the animal has a chance of falling, but the probability of falling is less than 50%, 1 point is given. You can jump onto the beam, but there is a chance you might fall off when walking on the balance beam. If the probability of falling is greater than 50%, the animal is given 2 points and is unable to balance using the normal side of its body. The animal is able to jump onto the beam, but the hind limb on the affected side cannot help move the body forward. If not, 3 points; the animal cannot walk on the balance beam, but on the wooden pole. If you can sit on it, give it 4 points. If you put the animal on a stick, it falls over immediately. will be worth 5 points.
[0159] (5) After scoring was completed, material collection began. After the mice were rapidly killed, the mouse brains were harvested and the mouse cerebral cortex (CP) was isolated. After exposing the mouse brain striatum, the striatum was collected and weighed, and PBS was added at a specified ratio. The mixture was then crushed and homogenized. The supernatant was then separated to determine the dopamine levels in the striatum. The amount of nicotine was detected.
[0160] 4. Detection of dopamine content in the striatum using a kit method
[0161] 4.1 The kit and some of the equipment are as follows:
[0162] [Table 12] Kit information JPEG2024543655000102.jpg199140
[0163] [Table 13] Major equipment and consumables JPEG2024543655000103.jpg199140
[0164] 4.2 Protein quantification (1) Preparation of a standard curve: Prepare an enzyme plate and add reagents according to the table below.
[0165] [Table 14] Reagents JPEG2024543655000104.jpg199140(2) Depending on the number of samples, mix BCA Reagent A and Reagent B in a volume ratio of 50:1 to prepare an appropriate A volume of BCA working solution was prepared and mixed thoroughly. (3) 160 μl of BCA working solution was added to each well. (4) Place the plate on an oscillator, shake for 30 seconds, and then leave it at 37°C for 30 minutes. The absorbance at 562 nm was measured. The horizontal axis represents absorbance, and the vertical axis represents protein concentration (μg / μl). was used to prepare a standard curve. (5) Add 2 μl of the test protein and 18 μl of PBS (10-fold dilution) to the plate. Add 160 μl of BCA working solution, place the plate on an oscillator, shake for 30 sec, and The mixture was allowed to stand at 7° C. for 30 minutes, after which the absorbance at 562 nm was measured. (6) Based on the absorbance value of the measured sample, the corresponding protein concentration on the standard curve is calculated. (μg / μl) and multiplying this by the sample dilution factor (10) gives the actual concentration of the sample. The concentration (unit: μg / μl) was obtained. (7) For the operation and method of the mouse dopamine detection experiment, please refer to the kit instruction manual. Ta.
[0166] 5. Immunohistochemistry of tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain measurement 5.1 Experimental materials
[0167] [Table 15] Main reagents JPEG2024543655000105.jpg199140
[0168] [Table 16] Major equipment and consumables JPEG2024543655000106.jpg199140
[0169] Preparation of solutions (1)PBS solution 8g NaCl, 0.2g KCl, 1.4 Na2HPO4 in 600ml ddH2O Dissolve 4 g of ammonium sulfate and 0.24 g of KH2PO4, and adjust the pH of the solution to 7.4 using HCl. The solution was adjusted to 1 L, filtered, autoclaved, and stored at room temperature. . (2) 0.1 mol / L sodium citrate buffer 0.1mol / L citric acid 3.8ml, 0.1mol / L sodium citrate 16.2ml l. Citric acid C6H8O7·H2O: molecular weight 210.14; 0.1 mol / L solution is 21.0 1g / L. Sodium citrate Na3C6H5O7·2H2O: molecular weight 294.12; 0.1 mol / L solution is 29.41 g / mL.
[0170] 5.2 Experimental Method
[0171] 5.2.1 Sample embedding and fixation (1) Collection and fixation of materials When cutting tissue, a sharp knife or scissors was used. When cutting tissue blocks, The tissue was cut by pulling the knife backward from the base. The thickness of the tissue mass was about 0.2-0.3 cm. The appropriate size is 1.5cm x 1.5cm x 0.3cm. The tissue was fixed in ethyl acetate for 48 hours.
[0172] (2) Washing and dehydration The fixed tissue was rinsed in running water to remove residual fixative and impurities. Using alcohol, dilute it to 50%, 70%, 85% or 100% until you get pure alcohol (absolute ethanol). %, 95%, and 100% ethanol for 2 hours each. Dehydration should be carried out in jars with lids to prevent loss of concentration and incomplete dehydration. Materials that require preservation can be dehydrated to 70% ethanol and left to stand, allowing for long-term storage. If extended storage is required, add an equal amount of glycerin.
[0173] (3) Transparency The tissue block was placed in a mixture of equal parts of pure ethanol and xylene and left for 2 hours. , place in pure xylene, leave for 2 hours, place again in pure xylene, and leave for 2 hours. The material becomes transparent, revealing the effect of the dehydration in the previous step. If the tissue is sufficiently dehydrated, it will be transparent. If the tissue has a white cloudy appearance, it is not sufficiently dehydrated. It indicates that you need to start over, but that if you do, the effect will be poor. When xylene is used for clarification, the xylene evaporates and dissolves in the moisture in the air. It is necessary to avoid absorbing the xylene and keep it anhydrous.
[0174] (4) Paraffin infiltration Paraffin infiltration must be performed in a thermostatic oven. First, the tissue material block is infused with molten paraffin. The specimens were immersed in a mixture of equal parts of xylene for 1-2 hours, then transferred to two liquids of molten paraffin. Each was soaked for about 3 hours.
[0175] (5)Embedding For embedding, the tissue block was thoroughly soaked in paraffin and then wrapped in paraffin. The specific method is as follows: First, prepare a paper box, pour molten paraffin into the box, and then pour the pre-warmed pipette into the box. Use the clamp to quickly lift the tissue block and place it flat, cut side down, on the bottom of the carton. Then, the carton was slowly lifted and placed flat in cold water. The paraffin on the surface had hardened. Immediately after the mixture is cooled, the paper box is plunged into water to rapidly solidify, and then removed after 30 minutes. did.
[0176] (6) Slicing Before slicing, place the paraffin block in a refrigerator at -20°C for at least 30 min. The slicer knife holder is attached to the slicer to make it firm. Fix and place the base of the paraffin block or fix the paraffin block and place the base of the paraffin block Adjust the blade and knife to the appropriate position so that the blade and the surface of the paraffin block form a 5 degree angle. The thickness of the slices on the slicer was adjusted to 4-7 μm before slicing.
[0177] 5.2.2 Immunohistochemical staining
[0178] (1) Baking and dewaxing The slides were placed in a thermostatic oven and baked at 65°C for 30 min. min and then in xylene II for 15 min.
[0179] (2) Hydration Deparaffinize sections in 100% alcohol, 95% alcohol, 85% alcohol, and 75% Each was immersed in alcohol for 5 minutes and then rinsed with tap water for 10 minutes.
[0180] (3) Antigen repair The specimen was then high-pressure restored in 0.01M sodium citrate buffer for 15 min, cooled naturally, and then resuspended in 0.02M The sections were washed with PBS for 3 min three times.
[0181] (4) Blocking Slides were placed in 3% H2O2 and incubated in a humidified box for 10 min to determine endogenous The active peroxidase activity was eliminated by washing with 0.02M PBS for 3 min three times.
[0182] (5) Primary antibody incubation Add primary antibody (1:2000 dilution) and incubate in a humidified box at room temperature for 1 Incubate for 3 hours (or overnight at 4℃). Wash with 0.02M PBS for 3 minutes x 3 times. Washed.
[0183] (6) Dual Antibody Incubation Add HRP-conjugated broad-spectrum secondary antibody dropwise and incubate in a humidified box at room temperature. The plate was left to stand for 20-30 minutes in 0.02M PBS, and then washed three times for 3 minutes with 0.02M PBS.
[0184] (7) Color development If discoloration was observed in the sections after DAB staining, the staining solution was immediately washed off with tap water.
[0185] (8) Hematoxylin staining Counterstain with hematoxylin for 3 minutes, differentiate with 1% hydrochloric acid alcohol, and observe under a microscope. The degree of dyeing was controlled. Rinse with tap water for 10 minutes and place in a 65℃ oven. The moisture was dried.
[0186] (9) Clearing and mounting The slides were cleared in xylene for 3 min twice, mounted in neutral resin, and incubated at 65°C. It was left in the oven for 15 minutes.
[0187] 5.2.3 Image collection and analysis Photographs were taken under a microscope, relevant parts of the samples were collected and analyzed, and the positive areas were calculated.
[0188] 6. Experimental Results (1) The results of the behavioral balance beam score of the Parkinson's disease model are shown in the following table and Figure 10. vinegar.
[0189] [Table 17] Behavioral balance beam score results for Parkinson's disease model JPEG2024543655000107.jpg199140
[0190] A Parkinson's disease model was created in mice by intraperitoneal injection of MPTP. Behavioral evaluation was performed using the balance beam score. Seven days after intraperitoneal injection of MPTP, Modeling was not performed for the blank group, and balance beam scores were The score for the remaining groups was 5 to 6 points. Compared with the blank group, P ≤ 0.05 was statistically significant, proving the success of the model. Ta.
[0191] After that, the positive drug group and each compound group were treated, and then the balance beam of the model group was The core score was 4-5 points, and the balance beam score for positive drugs was 2-3 points. The balance beam scores of the drug treatment group were 3 to 4 points. Compared with the model group, there was a trend toward a significant decrease, with P≦0.05, which was statistically significant. I did.
[0192] The scores of each group after treatment were as follows: blank group < positive drug group < compound 2 group < compound 1 group < model group. I did.
[0193] (2) The dopamine content in the striatum of the Parkinson's disease model after treatment is shown in the following table and figure. Shown in Figure 11.
[0194] Table 18. Striatal dopamine content in Parkinson's disease models after treatment JPEG2024543655000108.jpg199140
[0195] Dopamine, as a neurotransmitter, regulates various physiological functions of the central nervous system. The researchers detected dopamine levels in the striatum of mice treated with Parkinson's disease. By doing so, the effects of drug treatment on the Parkinson's disease model were confirmed.
[0196] The dopamine content of each group was compared with that of the blank group to determine the dopamine content in the model. As a result of judging the degree of dopamine reduction, the dopamine content of each compound group was significantly decreased except for the positive drug group. The abundance was significantly decreased, with P≦0.05, which was statistically significant.
[0197] Next, the dopamine content of the other compound groups was compared with that of the model group. The dopamine content in each group was increased compared with the model group, with P≦0.01. The results were statistically significant, indicating that each drug group had the effect of increasing dopamine content in the brain. It was done. Dopamine content in the striatum was as follows: blank group > positive drug group > compound 1 group > compound 2 group > model group It became.
[0198] (3) Immunohistochemistry of tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain The experimental results of the objective measurements are shown in the table below and in FIGS.
[0199] [Table 19] Immunohistochemistry of tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain Chemical measurement experiment results JPEG2024543655000109.jpg199140
[0200] Tyrosine hydroxylase (TH) is a monooxygenase that produces the organism's own L-dose. It is the rate-limiting enzyme that catalyzes the first step of a series of reactions in the synthesis of damin (DA) in cells. TH is abundant in neurons, and dopamine-β-hydroxylase is expressed only in the midbrain. Due to the lack of xylase, TH-immunoreactive neurons in the midbrain are DA neurons. It can be used as a marker for dopamine neurons in the brain. L-tyrosine is used to produce levodopa under the catalysis of xylase and aromatic decarboxylase The carboxyl group is removed from levodopa by catalysis, ultimately producing levodopamine. Tyrosine hydroxylase plays an important role in the synthesis of dopamine. Lack of function or insufficient expression of dopamine directly affects the synthesis and secretion of dopamine. Dopaminergic neurons synthesize dopamine, which is an important neurotransmitter. Developmental dysfunction or insufficient secretion can lead to the development of Parkinson's disease.
[0201] As a result of this experiment, a mouse model of Parkinson's disease was created by intraperitoneal injection of MPTP. In the mouse brain, tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) were positive. The rate was decreased, and the P value was ≦0.05, which was statistically significant. Compared with the model group. In the positive drug group, tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain were The positive rate of cells was significantly improved, indicating that the modeling was successful.
[0202] After treating a mouse Parkinson's disease model with each compound group, the effects of each compound were compared with those of the model group. In the group, the positive rate of tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain was increased Among them, compound 1 inhibited tyrosine hydroxylase in the substantia nigra (SubN) of the brain. The positive rate of (TH) cells was compared with the model group, with P≦0.01, which was statistically significant. It was.
[0203] Positive tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain in each group after treatment The rates were compared as follows: blank group > positive drug group > compound 1 group > compound 2 group > model group.
[0204] 7. Summary of the experiment In this experiment, MPTP (25 mg / kg) was intraperitoneally injected once daily for 7 consecutive days. A mouse Parkinson's model was created. The balance beam score was used to measure mouse Parkinson's disease. We performed screening against the model.
[0205] Next, the positive drug group and each compound group were intragastrically administered to the model mice for 14 consecutive days. After treatment, the balance beam scores of each group were analyzed, and dopamine levels in the striatum were measured by ELISA. The amount of tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain was detected. The ratio of each compound group to the blank group and the model group was detected by immunohistochemical detection. The differences were then ascertained and statistical analysis was performed to analyze the efficacy of each compound.
[0206] As confirmed by the balance beam score after treatment, the positive drug group was significantly higher than the model group. There was a significant tendency for a decrease in the concentration of α-glucose in each compound group, with P values of 0.05 and statistical significance. .
[0207] Next, the dopamine content of the other compound groups was compared with that of the model group. The dopamine content in each group was increased, with P≦0.01, which was statistically significant. .
[0208] After treating the mouse Parkinson's disease model with each compound and a positive drug, the positive drug group and each compound group were The positive rates of the two groups were compared with those of the model group. Among them, the compound 1 group showed a significant increase in the substantia nigra (S b) The positive rate of tyrosine hydroxylase (TH) cells in the N group was compared with that of the model group. The results were statistically significant, with P≦0.01.
[0209] Each compound group was compared with the model group for overall analysis to determine whether any of them had therapeutic effects, but with various Comparing the various detection indicators, it was found that compound 1 had a better therapeutic effect.
[0210] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements, etc. made within the spirit and principle of the present invention are within the scope of protection of the present invention. The scope of the scope of the
[0211] The above-described embodiments and methods described herein are subject to change based on the ability, experience, and preferences of those skilled in the art. It is possible.
[0212] In the present invention, the steps of the method are merely recited in a particular order, which is The order of the steps is not limited.
Claims
1. A compound having the following structure or a pharma- ceutically acceptable salt, stereoisomer, ester, or proline thereof: Drug, solvate. (I) (where: X 1 and X 2 are independently a single bond, a substituted or unsubstituted alkylene, one or more -C (=O)O- separated alkylene, one or more -OC(=O)- separated Separated alkylene, alkylene separated by one or more -C(=O)NH- are selected from X 3 teeth, 、 、 、 is selected from R 1 is selected from H, alkyl, cycloalkyl; R 2 is selected from OH, alkoxy; n is an integer from 1 to 5, R 3 H, is selected from Here, X 4 and X 5 are independently a single bond, a substituted or unsubstituted alkylene, one or more Alkylene separated by a number of -C(=O)O-, one or more -OC(=O)- an alkylene separated by one or more -C(=O)NH-; alkylene; X 6 teeth, 、 、 、 is selected from R 4 is selected from H, alkyl, cycloalkyl; R 5 is selected from OH, alkoxy; m is an integer from 1 to 5.
2. X 1 and X 4 is independently selected from a single bond, a C1-6 straight or branched chain alkylene; Preferably, X 1 is methylene, Preferably, X 4 The compound of claim 1, wherein is methylene.
3. X 2 The structure where R 7 is H, alkyl, alkyl substituted with alkylmercapto, hydroxy-substituted alkyl, mercapto-substituted alkyl, -C(=O)NH 2 alkyl substituted with , alkyl substituted with carboxy, alkyl substituted with amino 、 substituted alkyl, heterocyclylalkyl, aralkyl; Preferably, R 7 is H, methyl, isopropyl, sec-butyl, isobutyl, 、 、 、 、 、 、 、 、 、 、 、 、 、 2. The compound according to claim 1, wherein the compound is selected from the group consisting of:
4. X 5 The structure where R 8 is H, alkyl, alkyl substituted with alkylmercapto, hydroxy-substituted alkyl, mercapto-substituted alkyl, -C(=O)NH 2 alkyl substituted with , alkyl substituted with carboxy, alkyl substituted with amino 、 substituted alkyl, heterocyclylalkyl, aralkyl; Preferably, R 8 is H, methyl, isopropyl, sec-butyl, isobutyl, 、 、 、 、 、 、 、 、 、 、 、 、 、 2. The compound according to claim 1, wherein the compound is selected from the group consisting of:
5. R 2 and R 5 is independently selected from OH, C1-6 alkoxy; Preferably, R 2 is OH, methoxy or ethoxy, Preferably, R 5 is OH, methoxy or ethoxy. The compound described.
6. 2. The compound of claim 1 having the structure: or
7. 2. The compound of claim 1, wherein the stereoisomer has the following structure: (VI)
8. 8. The compound of claim 7, wherein the stereoisomer has the following structure: or
9. The compound according to any one of claims 1 to 8, or a pharma- ceutically acceptable salt or stereoisomer thereof. , esters, prodrugs, solvates, and one or more pharma- ceutically acceptable auxiliary materials. and a pharmaceutical composition comprising:
10. A compound according to any one of claims 1 to 8 in the preparation of a medicament for preventing and / or treating a disease. or a pharma- ceutically acceptable salt, stereoisomer, ester, prodrug, solvate thereof The use of an object, The disease is selected from the group consisting of nervous system diseases, cancer, autoimmune diseases, cardiovascular diseases, pain, inflammation, and liver damage. one or more selected from the group consisting of Preferably, the nervous system disease is epilepsy, multiple sclerosis, Parkinson's disease, Alzheimer's disease, or Selected from: Marr's disease, Lewy body dementia, Huntington's disease, anxiety, depression, Preferably, the cancer is breast cancer, lung cancer, colorectal cancer, liver cancer, pancreatic cancer, gastric cancer. , gastroesophageal adenocarcinoma, esophageal cancer, small intestine cancer, cardia cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, Selected from vulvar cancer, testicular cancer, prostate cancer, leukemia, and glioma. Preferably, the autoimmune disease is systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis. ulcerative colitis, Crohn's disease, and autoimmune hepatitis.
Citation Information
Patent Citations
Cannabinoid prodrug compounds
WO2021062231A2
